Huaier Aqueous Extract Combined with Gefitinib Promotes ACSL4-Dependent Ferroptosis and Overcomes Gefitinib Resistance in Non-Small Cell Lung Cancer

Abstract

Objective

Huaier, a traditional Chinese medicine (TCM) approved by the National Medical Products Administration (NMPA) of China for cancer therapy, demonstrates broad antitumor activity. However, its potential to overcome resistance to gefitinib, a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in non-small cell lung cancer (NSCLC) and the underlying mechanisms remain unclear. This study aimed to determine whether Huaier aqueous extract enhances the efficacy of gefitinib against resistant NSCLC and to elucidate the molecular basis of this effect.

Methods

Cell proliferation was evaluated using the Cell Counting Kit-8 and colony formation assays. Apoptosis, reactive oxygen species (ROS), and lipid ROS were measured using flow cytometry, and mitochondrial morphology was examined using transmission electron microscopy. RNA sequencing and integrated bioinformatics analyses of GEO datasets were performed to identify ferroptosis-related genes, which were validated by qPCR and Western blotting. The in vivo efficacy was assessed using a PC-9GR xenograft model.

Results

Huaier aqueous extract significantly enhanced the sensitivity of gefitinib-resistant NSCLC cells to gefitinib in vitro, and suppressed tumor growth in vivo. Mechanistically, the combined treatment activated the ferroptosis pathway, accompanied by the upregulation of acyl-CoA synthetase long-chain family member 4 (ACSL4). Pharmacological inhibition of ferroptosis or ACSL4 partially attenuated the antitumor effect, confirming their key roles in mediating the synergistic activity of Huaier aqueous extract and gefitinib.

Conclusions

Huaier aqueous extract reversed gefitinib resistance in NSCLC cells by promoting ACSL4-dependent ferroptosis, thereby providing a promising therapeutic strategy for improving EGFR-TKI efficacy.

Keywords

Non-small cell lung cancer (NSCLC) / Huaier / Ferroptosis / Gefitinib resistance / ACSL4 / Traditional Chinese Medicine

References

[1] Siegel RL, Miller KD, Wagle NS, et al.. Cancer statistics, 2023. CA Cancer J Clin., 2023, 73(1): 17-48

[2] Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol., 2023, 20(9): 624-639

[3] Hirsch FR, Scagliotti GV, Mulshine JL, et al.. Lung cancer: current therapies and new targeted treatments. Lancet., 2017, 389(10066): 299-311

[4] Levantini E, Maroni G, Del Re M, et al.. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol., 2022, 85: 253-275

[5] Passaro A, Jänne PA, Mok T, et al.. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer., 2021, 2(4): 377-391

[6] Meyer ML, Fitzgerald BG, Paz-Ares L, et al.. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet., 2024, 404(10454): 803-822

[7] Riely GJ, Wood DE, Ettinger DS, et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(4):249–274.

[8] Sim EH, Yang IA, Wood-Baker R, et al. Gefitinib for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2018;1(1):CD006847.

[9] Guo H, Wang H, Gao M, et al.. Harnessing the CD44-targeted delivery of self-assembled hyaluronan nanogel to reverse the antagonism between Cisplatin and Gefitinib in NSCLC cancer therapy. Carbohydr Polym., 2024, 344 122521

[10] Lim SM, Fujino T, Kim C, et al.. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res., 2023, 29(16): 3004-3016

[11] Lee EJ, Oh SY, Lee YW, et al.. Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC. Clin Cancer Res., 2024, 30(8): 1582-1594

[12] Xu C, Zhang L, Wang D, et al.. Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer. Cell Death Discov., 2021, 7(1): 353

[13] Zhu Y, Ouyang Z, Du H, et al.. New opportunities and challenges of natural products research: When target identification meets single-cell multiomics. Acta Pharm Sin B., 2022, 12(114011-4039

[14] Jin H, Liu C, Liu X, et al.. Huaier suppresses cisplatin resistance in non-small cell lung cancer by inhibiting the JNK/JUN/IL-8 signaling pathway. J Ethnopharmacol., 2024, 319(Pt 2 117270

[15] Xie K, Ma M, Xu F. Long-term oral administration of Huaier granules improves survival outcomes in hepatocellular carcinoma patients within Milan criteria following microwave ablation: a propensity score matching and stabilized inverse probability weighting analysis. Front Pharmacol., 2024, 15: 1336347

[16] Wang Y, Jia J, Wang Q, et al.. Secondary Metabolites from the Cultures of Medicinal Mushroom Vanderbylia robiniophila and Their Tyrosinase Inhibitory Activities. J Fungi (Basel)., 2023, 9(7): 702

[17] Li X, Zhang H, Deng Y, et al.. Huaier polysaccharides inhibits hepatocellular carcinoma via gut microbiota mediated M2 macrophage polarization. Int J Biol Macromol., 2025, 293 139357

[18] Chen Q, Shu C, Laurence AD, et al.. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut., 2018, 67(112006-2016

[19] Wang Z, Yu XL, Zhang J, et al.. Huaier granule prevents the recurrence of early-stage hepatocellular carcinoma after thermal ablation: A cohort study. J Ethnopharmacol., 2021, 281 114539

[20] Shi K, Bi Y, Zeng X, et al.. Effects of adjuvant huaier granule therapy on survival rate of patients with hepatocellular carcinoma. Front Pharmacol., 2023, 14: 1163304

[21] Guo Q, Peng Y, Zhang G, et al.. Effect of Huaier granule on prognosis of breast cancer: A single-center propensity score matching retrospective study. Chin Med J (Engl)., 2025, 138(193-98

[22] Zhang Y, Wang X, Chen T. Efficacy of Huaier granule in patients with breast cancer. Clin Transl Oncol., 2019, 21(5588-595

[23] Qi J, Xie FJ, Liu S, et al.. Huaier Granule Combined with Tegafur Gimeracil Oteracil Potassium Promotes Stage IIb Gastric Cancer Prognosis and Induces Gastric Cancer Cell Apoptosis by Regulating Livin. Biomed Res Int., 2020, 2020: 2403595

[24] Cui Y, Meng H, Liu W, et al.. Huaier aqueous extract induces apoptosis of human fibrosarcoma HT1080 cells through the mitochondrial pathway. Oncol Lett., 2015, 9(4): 1590-1596

[25] Yang A, Zhao Y, Wang Y, et al.. Huaier suppresses proliferative and metastatic potential of prostate cancer PC3 cells via downregulation of Lamin B1 and induction of autophagy. Oncol Rep., 2018, 39(63055-3063

[26] Xu Z, Zheng G, Wang Y, et al.. Aqueous Huaier Extract Suppresses Gastric Cancer Metastasis and Epithelial to Mesenchymal Transition by Targeting Twist. J Cancer., 2017, 8(18): 3876-3886

[27] Yan L, Liu X, Yin A, et al.. Huaier aqueous extract inhibits cervical cancer cell proliferation via JNK/p38 pathway. Int J Oncol., 2015, 47(3): 1054-1060

[28] Hu Z, Yang A, Fan H, et al.. Huaier aqueous extract sensitizes cells to rapamycin and cisplatin through activating mTOR signaling. J Ethnopharmacol., 2016, 186: 143-150

[29] Liu Z, Liu C, Yan K, et al.. Huaier Extract Inhibits Prostate Cancer Growth via Targeting AR/AR-V7 Pathway. Front Oncol., 2021, 11 615568

[30] Fu Z, Ma K, Dong B, et al.. The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells. BMC Complement Altern Med., 2019, 19(1): 203

[31] Yang L, Song Z, Wang X, et al.. Huaier extract enhances the treatment efficacy of paclitaxel in breast cancer cells via the NF-kappaB/IkappaBalpha pathway. Oncol Rep., 2017, 38(63455-3464

[32] Wang Q, Gong M, Liu R, et al.. Huaier enhances the tumor-killing effect and reverses gemcitabine-induced stemness by suppressing FoxM1. Phytomedicine., 2024, 129 155656

[33] Qu P, Han J, Qiu Y, et al.. Huaier extract enhances the treatment efficacy of imatinib in Ik6⁺ Ph⁺ acute lymphoblastic leukemia. Biomed Pharmacother., 2019, 117 109071

[34] Xu JY, Li JX, Zhao ZL, et al.. On huaier particles combined gefitinib in advanced lung adenocarcinoma. Med Philos (Chinese)., 2014, 35(3B): 30-32

[35] Lv F, Li X, Wang Y. An extraction from Trametes robiniophila Murr. (Huaier) inhibits non-small cell lung cancer proliferation via targeting to epidermal growth factor receptor. Bioengineered. 2022;13(4):10931–10943.

[36] Brown AR, Hirschhorn T, Stockwell BR. Ferroptosis-disease perils and therapeutic promise. Science., 2024, 386(6724): 848-849

[37] Li J, Cao F, Yin HL, et al.. Ferroptosis: past, present and future. Cell Death Dis., 2020, 11(2): 88

[38] Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell., 2024, 42(4513-534

[39] Liao P, Wang W, Wang W, et al.. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell., 2022, 40(4): 365-378.e6

[40] Tian YY, Yang AL, Chen XN, et al.. Effect of Huaier aqueous extract on growth and metastasis of human non-small cell lung cancer NCI-H1299 cells and its underlying mechanisms. Zhongguo Zhong Yao Za Zhi (Chinese)., 2020, 45(15): 3700-3706

[41] Zhu Z, Wang X, Zhang W, et al.. Huaier suppresses pancreatic cancer progression via activating cell autophagy induced ferroptosis. Front Oncol., 2022, 12 960858

[42] Li C, Wang X, Chen T, et al.. Trametes robiniophila Murr in the treatment of breast cancer. Biomed Pharmacother., 2020, 128 110254

[43] Zhang J, Mao P, Zhou T, et al.. Macrophage ferroptosis potentiates GCN2 deficiency induced pulmonary venous arterialization. Nat Commun., 2025, 16(1): 8335

[44] Dai Y, Chen Y, Mo D, et al.. Inhibition of ACSL4 ameliorates tubular ferroptotic cell death and protects against fibrotic kidney disease. Commun Biol., 2023, 6(1907

[45] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 2014, 15(12550

[46] Kanehisa M, Furumichi M, Sato Y, et al.. KEGG: biological systems database as a model of the real world. Nucleic Acids Res., 2025, 53(D1D672-D677

[47] Ritchie ME, Phipson B, Wu D, et al.. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 2015, 43(7 e47

[48] Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6):bbab260.

[49] Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955–61.

[50] Liao C, Wang X. TCGAplot: an R package for integrative pan-cancer analysis and visualization of TCGA multi-omics data. BMC Bioinformatics., 2023, 24(1): 483

[51] Győrffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation (Camb)., 2024, 5(3100625

[52] Wu T, Liu S, Chen W, et al.. Huaier suppresses cell viability, migration and invasion in human non-small cell lung cancer via lncRNA DLEU2/miR-212-5p/ELF3 axis. Int J Med Sci., 2024, 21(2319-331

[53] Sun C, Gao W, Liu J, et al.. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Respir Res., 2020, 21(1): 210

[54] Pan YH, Jiao L, Lin CY, et al.. Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway. Biologics., 2018, 12: 75-86

[55] Wu T, Chen W, Liu S, et al.. Huaier suppresses proliferation and induces apoptosis in human pulmonary cancer cells via upregulation of miR-26b-5p. FEBS Lett., 2014, 588(122107-2114

[56] Zhong WZ, Wang Q, Mao WM, et al.. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1–N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol., 2021, 39(7): 713-722

[57] Han R, Li J, Wang Y, et al.. Low BMI patients with advanced EGFR mutation-positive NSCLC can get a better outcome from metformin plus EGFR-TKI as first-line therapy: A secondary analysis of a phase 2 randomized clinical trial. Chin Med J Pulm Crit Care Med., 2023, 1(2): 119-124

[58] Zhang Y, Qian J, Fu Y, et al.. Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer. Biochim Biophys Acta Mol Basis Dis., 2024, 1870(7 167447

[59] Liam CK, Ahmad AR, Hsia TC, et al.. Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis. Clin Cancer Res., 2023, 29(10): 1879-1886

[60] Tang Q, Xu M, Long S, et al.. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma. J Ethnopharmacol., 2024, 318(Pt A 116646

[61] Wang J, He X, Jia Z, et al.. Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway. Pharm Biol., 2024, 62(1): 33-41

[62] Yao W, Liu C, Zhang N, et al.. Atractyloside inhibits gefitinib-resistant non-small-cell lung cancer cell proliferation. Oncol Lett., 2024, 28(4): 466

[63] Ni J, Chen K, Zhang J, et al.. Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells. Biochem Biophys Res Commun., 2021, 567: 154-160

[64] Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell., 2022, 185(142401-2421

[65] Lin J, Lai Y, Lu F, et al.. Targeting ACSLs to modulate ferroptosis and cancer immunity. Trends Endocrinol Metab., 2025, 36(7): 677-690

[66] Zhang Y, Li S, Li F, et al.. High-fat diet impairs ferroptosis and promotes cancer invasiveness via downregulating tumor suppressor ACSL4 in lung adenocarcinoma. Biol Direct., 2021, 16(1): 10

[67] Alali M, Saifo M. Optimizing the Treatment for Advanced Non-Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review. J Immunother Precis Oncol., 2023, 6(3140-149

[68] Fukuda A, Okuma Y. From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res., 2024, 30(15): 3128-3136

Funding

National Natural Science Foundation of China(No.82200113)

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to the Huazhong University of Science and Technology

Just Accepted

This article has successfully passed peer review and final editorial review, and will soon enter typesetting, proofreading and other publishing processes. The currently displayed version is the accepted final manuscript. The officially published version will be updated with format, DOI and citation information upon launch. We recommend that you pay attention to subsequent journal notifications and preferentially cite the officially published version. Thank you for your support and cooperation.